Verona Pharma trades as part of the healthcare sector and is part of the biotechnology industry. The company CEO is Sven Jan-Anders Karlsson. Verona Pharma develops drugs for respiratory diseases. Its products mainly include anti-inflammatory agents and bronchodilators.

Previous Intraday Performance:

The VRNA shares had a previous change of 6.43% which opened at 5.91 and closed at 5.91. It moved to an intraday high of 6.29 and a low of 5.87.

SeekingAlpha:  Verona Pharma (VRNA) Presents At American Thoracic Society International Conference – Slideshow

Historical Performance:

Over the last five trading days, VRNA shares returned -0.17% and in the past 30 trading days it returned -6.57%. Over three months, it changed 2.07%. In one year it has changed -63.34% and within that year its 52 week high was 17.16 and its 52 week low was 5.52. VRNA stock is 7.07% above its 52 week low.

Our calculations result in a 200 day moving average of 9.20 and a 50 day moving average of 6.32. Right now, VRNA stock is trading -35.76% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Verona Pharma (VRNA) Presents At American Thoracic Society International Conference – Slideshow


The company has a market cap of $82.8m with 13.2m shares outstanding and a float of 13.2m shares. Trading volume was 6,295 shares and has experienced an average volume of 4,988 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Verona Pharma was -1.93 which ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.57.

1stQtr 2019 -0.544thQtr 2018 -0.283rdQtr 2018 -0.232ndQtr 2018 0.061stQtr 2018 -1.62

The growth of the EPS is critical in understanding the current valuation of Verona Pharma.

Indicators Also to Watch:

Based on the latest filings, there is 54.80% of institutional ownership.

The beta was calculated to be -0.98.

SeekingAlpha:  Vermillion reports Q1 results

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -16.30%, return on assets is -13.61% and price-to-book is 1.06.

Company Score Card:

Results are out of six:
 1  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here